Precision Mental Health in Diabetes - Subtypes of Mental Health, Trajectories, and Patterns With Glycaemic Control
Launched by FORSCHUNGSINSTITUT DER DIABETES AKADEMIE MERGENTHEIM · Sep 19, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The PRO-MENTAL trial is a research study looking at how mental health affects people with diabetes, specifically focusing on those with type 1 and type 2 diabetes. The goal is to understand the different types of mental health challenges, like depression and anxiety, and how these issues relate to managing blood sugar levels (glycemic control) over time. By studying 1,500 participants over two years, researchers hope to find patterns in mental health and diabetes care that can lead to personalized treatments and better support for individuals facing these challenges.
To participate, you need to be between 18 and 75 years old and have been diagnosed with type 1 or type 2 diabetes for at least a year. If you join, you'll complete a series of questionnaires and assessments every six months, which include questions about your mental well-being, daily mood, and stress, as well as monitoring your blood sugar levels. This study aims to create a better understanding of how mental health and diabetes interact, ultimately helping to develop tailored interventions that suit the specific needs of different people with diabetes.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age between 18 and 75 years
- • Diagnosis of type 1 diabetes (T1D) or type 2 diabetes (T2D)
- • Diabetes duration ≥ 1 year
- • Sufficient German language skills
- • Written informed consent
- Exclusion Criteria:
- • Inability to consent,
- • Significant cognitive impairment (e.g., cognitive disorder, dementia)
- • Severe somatic disease or mental disorder likely to impede study participation or confound results (e.g., severe heart failure ≥ NYHA III; cancer requiring treatment; dialysis-dependent nephropathy; schizophrenia/psychotic disorder)
- • Terminal illness
- • Being bedridden
About Forschungsinstitut Der Diabetes Akademie Mergentheim
The Forschungsinstitut der Diabetes Akademie Mergentheim is a leading clinical research organization dedicated to advancing diabetes care through innovative research and development. With a focus on conducting high-quality clinical trials, the institute collaborates with academic institutions, healthcare providers, and pharmaceutical companies to explore new therapeutic approaches and enhance patient outcomes. Committed to excellence in research and ethical standards, the institute plays a pivotal role in shaping the future of diabetes treatment and management.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bad Mergentheim, Baden Württemberg, Germany
Bad Mergentheim, Baden Württemberg, Germany
Bad Mergentheim, , Germany
Bad Mergentheim, , Germany
Patients applied
Trial Officials
Norbert Hermanns, Prof, PhD
Principal Investigator
Research Institute Diabetes Academy Mergentheim (FIDAM)
Bernhard Kulzer, Prof, PhD
Principal Investigator
Research Institute Diabetes Academy Mergentheim (FIDAM)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials